Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 27 October 2024

Created: 27 October 2024

Last Updated: 27 October 2024

CAMBRIDGE, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in people living with IgA nephropathy (IgAN). The results showed substantial reductions in proteinuria, stabilization of kidney function, and sustained treatment effect more than 18…

Posted: 2024-10-27 00:15:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related Bing News Search Results

Press Release: Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 - Newscast

Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?

Fri, 14 Mar 2025 08:30:35 GMT It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 1.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug

Fri, 28 Feb 2025 08:00:00 GMT The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's drug, Leqembi, after concluding a safety review.

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Fri, 28 Feb 2025 05:23:00 GMT TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Thu, 27 Feb 2025 21:24:00 GMT Viehbacher, "Biogen") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti ...